Form 4: Precision BioSciences CEO Sells Shares for Tax

Precision BioSciences CEO Michael Amoroso sold 20,559 shares of common stock to cover tax obligations following the vesting of restricted stock units.

Summary

• Michael Amoroso, President and CEO, and a Director of Precision BioSciences Inc. (DTIL), reported transactions involving the company's common stock.
• On February 17, 2026, 67,797 Restricted Stock Units (RSUs) vested, representing a contingent right to receive one share of common stock per RSU.
• Following the vesting, Mr. Amoroso beneficially owned 263,951 shares of common stock.
• On February 18, 2026, Mr. Amoroso sold 20,559 shares of common stock at a price of $3.84 per share.
• This sale was a 'sell-to-cover' transaction, executed solely to satisfy tax withholding obligations related to the RSU vesting and settlement.
• The sale was conducted pursuant to a Rule 10b5-1 plan adopted on August 2, 2024.
• After the sale, Mr. Amoroso beneficially owns 243,392 shares of common stock directly.
• Additionally, 135,593 derivative securities (RSUs) remain beneficially owned directly, which vest in three substantially equal annual installments beginning February 17, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. The vesting of RSUs is a positive compensation event for the executive, but the subsequent sale is a routine 'sell-to-cover' for tax purposes and does not reflect a discretionary decision to reduce ownership based on company performance or outlook.

Positives

• The vesting of 67,797 Restricted Stock Units (RSUs) indicates a compensation event for the CEO, aligning executive incentives with shareholder value over time.

Negatives

• The sale of 20,559 shares of common stock reduces the CEO's direct beneficial ownership, although it was solely for tax purposes.

Future Outlook

The remaining 135,593 Restricted Stock Units held by Michael Amoroso are scheduled to vest in three substantially equal annual installments, commencing on February 17, 2026, contingent upon his continued service to the Issuer.

Industry Context

StockSavvy.ai notes that insider transactions, particularly 'sell-to-cover' events like this, are common occurrences for executives receiving equity compensation. These sales are typically not indicative of a change in management's outlook on the company's prospects but rather a standard mechanism to manage tax liabilities associated with vested equity awards. Such transactions are generally viewed as neutral by the market, especially when executed under a pre-arranged Rule 10b5-1 plan, which aims to prevent trading on material non-public information.

Comparison to Industry Standards

• This Form 4 filing reports an insider transaction, specifically a 'sell-to-cover' event, which is a standard practice across all industries for executives receiving equity compensation.
• The use of a Rule 10b5-1 plan aligns with best practices for corporate governance, providing an affirmative defense against insider trading allegations by pre-scheduling trades.

Corporate Governance

Stakeholder Impact

• Shareholders: The reduction in the CEO's direct shareholding due to a 'sell-to-cover' transaction is generally considered neutral, as it's a common practice for tax management and not a discretionary sale.
• Employees: The vesting of RSUs is part of executive compensation, which can indirectly influence employee morale and retention strategies.

Next Steps

• Future vesting of the remaining 135,593 Restricted Stock Units in substantially equal annual installments beginning February 17, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine 'sell-to-cover' transaction by the CEO to satisfy tax obligations upon RSU vesting. Such transactions are generally not indicative of a change in the company's fundamental prospects or the executive's confidence. Therefore, a seasoned investor would likely maintain their current position, as this event alone does not provide a strong signal for a buy or sell decision.

Keywords

DTIL, Precision BioSciences, Michael Amoroso, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Sell-to-Cover, Rule 10b5-1 Plan, Executive Compensation